Eli Lilly's Stock Tumbles 15% After Disappointing Obesity Pill Trial Results
Eli Lilly's shares dropped 15% after its obesity pill, orforglipron, failed in Phase III trials, failing to compete with Novo Nordisk's Ozempic, despite positive earnings.
Eli Lilly's shares dropped 15% after its obesity pill, orforglipron, failed in Phase III trials, failing to compete with Novo Nordisk's Ozempic, despite positive earnings.
